Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world - 2ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
- 3Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
- 4'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
- 5Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- Exploring School Life: Self-awareness and Illustrations
- How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- How to avoid or deal with an outrageous medical bill
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- What to know about new CDC deputy director who has been critical of COVID vaccines
- Vote In favor of Your Favored Kind Of Attire
- As tetanus vaccination rates decline, doctors worry about rising case numbers
